These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34813168)

  • 21. Remdesivir Strongly Binds to Both RNA-Dependent RNA Polymerase and Main Protease of SARS-CoV-2: Evidence from Molecular Simulations.
    Nguyen HL; Thai NQ; Truong DT; Li MS
    J Phys Chem B; 2020 Dec; 124(50):11337-11348. PubMed ID: 33264025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structure-based virtual screening and molecular dynamics simulation of SARS-CoV-2 Guanine-N7 methyltransferase (nsp14) for identifying antiviral inhibitors against COVID-19.
    Selvaraj C; Dinesh DC; Panwar U; Abhirami R; Boura E; Singh SK
    J Biomol Struct Dyn; 2021 Aug; 39(13):4582-4593. PubMed ID: 32567979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Benchmark of Popular Free Energy Approaches Revealing the Inhibitors Binding to SARS-CoV-2 Mpro.
    Ngo ST; Tam NM; Pham MQ; Nguyen TH
    J Chem Inf Model; 2021 May; 61(5):2302-2312. PubMed ID: 33829781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein-Ligand Docking Simulations with AutoDock4 Focused on the Main Protease of SARS-CoV-2.
    de Azevedo Junior WF; Bitencourt-Ferreira G; Godoy JR; Adriano HMA; Dos Santos Bezerra WA; Dos Santos Soares AM
    Curr Med Chem; 2021; 28(37):7614-7633. PubMed ID: 33781188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Computational discovery of small drug-like compounds as potential inhibitors of SARS-CoV-2 main protease.
    Andrianov AM; Kornoushenko YV; Karpenko AD; Bosko IP; Tuzikov AV
    J Biomol Struct Dyn; 2021 Sep; 39(15):5779-5791. PubMed ID: 32662333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of Potent SARS-CoV-2 Inhibitors from Approved Antiviral Drugs via Docking and Virtual Screening.
    Chtita S; Belhassan A; Aouidate A; Belaidi S; Bouachrine M; Lakhlifi T
    Comb Chem High Throughput Screen; 2021; 24(3):441-454. PubMed ID: 32748740
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Molecular docking and simulation studies on SARS-CoV-2 M
    Lokhande KB; Doiphode S; Vyas R; Swamy KV
    J Biomol Struct Dyn; 2021 Nov; 39(18):7294-7305. PubMed ID: 32815481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potential of NO donor furoxan as SARS-CoV-2 main protease (M
    Al-Sehemi AG; Pannipara M; Parulekar RS; Patil O; Choudhari PB; Bhatia MS; Zubaidha PK; Tamboli Y
    J Biomol Struct Dyn; 2021 Sep; 39(15):5804-5818. PubMed ID: 32643550
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anthocyanin derivatives as potent inhibitors of SARS-CoV-2 main protease: An in-silico perspective of therapeutic targets against COVID-19 pandemic.
    Fakhar Z; Faramarzi B; Pacifico S; Faramarzi S
    J Biomol Struct Dyn; 2021 Oct; 39(16):6171-6183. PubMed ID: 32741312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plitidepsin: Mechanisms and Clinical Profile of a Promising Antiviral Agent against COVID-19.
    Papapanou M; Papoutsi E; Giannakas T; Katsaounou P
    J Pers Med; 2021 Jul; 11(7):. PubMed ID: 34357135
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes and clinical characteristics of the compassionate use of plitidepsin for immunocompromised adult patients with COVID-19.
    Aguareles J; Fernández PV; Carralón-González MM; Izquierdo CF; Martí-Ballesteros EM; Fernández VP; Sotres-Fernandez G; García-Delangue T; LaPetra RGV; Sánchez-Manzano MD; Gutiérrez C; García-Coca M; Carnevali-Ruiz D; Barrena-Puertas R; Luque-Pinilla JM; Lloris R; Luepke-Estefan XE; López-Martín JA; Jimeno JM; Guisado-Vasco P
    Int J Infect Dis; 2023 Oct; 135():12-17. PubMed ID: 37481109
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Maurya AK; Mishra N
    J Biomol Struct Dyn; 2021 Nov; 39(18):7306-7321. PubMed ID: 32835632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: an
    Elfiky AA
    J Biomol Struct Dyn; 2021 Jun; 39(9):3204-3212. PubMed ID: 32338164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In silico drug discovery of major metabolites from spices as SARS-CoV-2 main protease inhibitors.
    Ibrahim MAA; Abdelrahman AHM; Hussien TA; Badr EAA; Mohamed TA; El-Seedi HR; Pare PW; Efferth T; Hegazy MF
    Comput Biol Med; 2020 Nov; 126():104046. PubMed ID: 33065388
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In silico evidence of beauvericin antiviral activity against SARS-CoV-2.
    Al Khoury C; Bashir Z; Tokajian S; Nemer N; Merhi G; Nemer G
    Comput Biol Med; 2022 Feb; 141():105171. PubMed ID: 34968860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Plitidepsin as an Immunomodulator against Respiratory Viral Infections.
    Losada A; Izquierdo-Useros N; Aviles P; Vergara-Alert J; Latino I; Segalés J; Gonzalez SF; Cuevas C; Raïch-Regué D; Muñoz-Alonso MJ; Perez-Zsolt D; Muñoz-Basagoiti J; Rodon J; Chang LA; Warang P; Singh G; Brustolin M; Cantero G; Roca N; Pérez M; Bustos-Morán E; White K; Schotsaert M; García-Sastre A
    J Immunol; 2024 Apr; 212(8):1307-1318. PubMed ID: 38416036
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plitidepsin has a positive therapeutic index in adult patients with COVID-19 requiring hospitalization.
    Varona JF; Landete P; Lopez-Martin JA; Estrada V; Paredes R; Guisado-Vasco P; de Orueta LF; Torralba M; Fortún J; Vates R; Barberán J; Clotet B; Ancochea J; Carnevali D; Cabello N; Porras L; Gijón P; Monereo A; Abad D; Zúñiga S; Sola I; Rodon J; Izquierdo-Useros N; Fudio S; Pontes MJ; de Rivas B; Girón de Velasco P; Sopesén B; Nieto A; Gómez J; Avilés P; Lubomirov R; White KM; Rosales R; Yildiz S; Reuschl AK; Thorne LG; Jolly C; Towers GJ; Zuliani-Alvarez L; Bouhaddou M; Obernier K; Enjuanes L; Fernández-Sousa JM; ; Krogan NJ; Jimeno JM; García-Sastre A
    medRxiv; 2021 May; ():. PubMed ID: 34075384
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design of hACE2-based small peptide inhibitors against spike protein of SARS-CoV-2: a computational approach.
    Dhingra N; Bhardwaj R; Bhardwaj U; Kapoor K
    Struct Chem; 2023 Jan; ():1-14. PubMed ID: 36714014
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Plitidepsin as Potent Inhibitor of SARS-CoV-2-Induced Cytopathic Effect After a Drug Repurposing Screen.
    Rodon J; Muñoz-Basagoiti J; Perez-Zsolt D; Noguera-Julian M; Paredes R; Mateu L; Quiñones C; Perez C; Erkizia I; Blanco I; Valencia A; Guallar V; Carrillo J; Blanco J; Segalés J; Clotet B; Vergara-Alert J; Izquierdo-Useros N
    Front Pharmacol; 2021; 12():646676. PubMed ID: 33841165
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Plitidepsin: design, development, and potential place in therapy.
    Alonso-Álvarez S; Pardal E; Sánchez-Nieto D; Navarro M; Caballero MD; Mateos MV; Martín A
    Drug Des Devel Ther; 2017; 11():253-264. PubMed ID: 28176904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.